Reading view
Toward Robust Personalized Alignment for LLMs: Mitigating Persona Drift in Multi-Turn Dialogue
BlueLM-GUI Technical Report: A Real-Device-Centric Flywheel for Self-Improving Mobile GUI Agents
Beyond the Query: Do Retrieval Signals Improve Adaptive Multimodal RAG Routing?
Bridging the Gap in Ophthalmic AI: MM-Retinal-Reason Dataset and OphthaReason Model toward Dynamic Multimodal Reasoning
Hurdle-RMIL: Addressing Zero Inflation and Long-Tailed Imbalance in Infrared Rainfall Retrieval
VBVR-Pro: A Scalable and Verifiable Suite for Native Visual Reasoning
An engineered nanopore identifies saccharides, amino acids, peptides and ribonucleotides
Nature Biotechnology, Published online: 14 September 2026; doi:10.1038/s41587-026-03308-9
Modified nanopore simultaneously identifies diverse biomolecules and their modifications.Key Experimental Therapeutics and Knowledge Gaps in Metabolic Dysfunction-Associated Steatohepatitis (MASH)
Drug Des Devel Ther. 2026 Sep 5;20:543657. doi: 10.2147/DDDT.S543657. eCollection 2026.
ABSTRACT
Metabolic dysfunction-associated steatohepatitis (MASH) is not solely a disorder of hepatocellular lipid accumulation, but a multicellular disease driven by coordinated metabolic stress, sterile inflammation, fibrogenesis, and niche remodeling. Recent therapeutic progress with the provisional approval of resmetirom and semaglutide has validated MASH as a tractable clinical target. However, many experimental agents have shown limited or inconsistent efficacy, particularly for regression of hepatic fibrosis or cirrhosis, reflecting the biological heterogeneity and dynamic cellular architecture of the disease. Distinct from conventional pathway- or drug class-based reviews, we summarize emerging therapeutics through a liver cell-centered framework, integrating hepatocyte-directed metabolic therapies, immune-cell modulation, hepatic stellate cell-targeted antifibrotic strategies, niche-directed approaches involving liver sinusoidal endothelial cells and cholangiocytes, systemic multi-cell modulators, and precision-delivery technologies. We further compare how these interventions reshape pathogenic communication among hepatic and extrahepatic compartments, while emphasizing unresolved challenges in drug target selection, cellular specificity, disease-stage dependency, safety, and patient stratification. This perspective emphasizes the need to move from isolated pathway targeting toward cell- and network-informed therapeutic strategies supported by spatial multi-omics, human-relevant models, and precision delivery.
PMID:42719321 | PMC:PMC13557022 | DOI:10.2147/DDDT.S543657
Impact of LLM-supported patient education on patient perspectives and patient-reported outcomes: a mixed-methods systematic review
npj Digital Medicine, Published online: 10 September 2026; doi:10.1038/s41746-026-03228-7
Impact of LLM-supported patient education on patient perspectives and patient-reported outcomes: a mixed-methods systematic reviewTransduction Efficiency in Clinical CAR T-Cell Products: A Retrospective Study at a Single Center
Ammonium tetrathiomolybdate improves auditory and vestibular function after gentamicin exposure via the NRF2–GPX4 axis
MITF-SCD1 Lipid Metabolic Axis Prevents Ouabain-Induced Spiral Ganglion Neuron Ferroptosis and Hearing Loss
Antisense oligonucleotides against Il6ra ameliorate cancer cachexia in mice
A complement C5-targeted GalNAc-conjugated siRNA with sustained efficacy in a non-human primate model of IgA nephropathy
The DreAM-plus integrative RNA switch enhances transient AAV expression and reduces side effects of gene editing
A helicase-fused Cas9 improves large-size fragment knockin
Author Correction: Nanopore-enabled time-resolved monitoring of catecholamine-related phenylalanine metabolism
Nature Nanotechnology, Published online: 09 September 2026; doi:10.1038/s41565-026-02294-y
Author Correction: Nanopore-enabled time-resolved monitoring of catecholamine-related phenylalanine metabolism